CervoMed to Participate in Upcoming Investor Conferences

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:

Leerink Global Healthcare Conference Format: 1x1 Investor Meetings Date: Wednesday, March 11, 2026

38 th Annual ROTH Conference Format: Fireside Chat & 1x1 Investor Meetings Presentation Date: Monday, March 23, 2026 Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://ir.cervomed.com/news-events/events-and-presentations

About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding.

Contacts:

Media: Lisa Guiterman Biongage Communications [email protected] 202-330-3431

Investor Relations: Argot Partners cervomed@argotpartners.com 212-600-1902